When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study
Xincheng Jiang,
Xiaoyan Han,
Fengyan Jin,
Gang An,
Jian Hou,
Jingsong He,
Qingming Wang,
Wenjun Wu,
Yi Zhao,
Songfu Jiang,
Shuchan Li,
Zhenshu Xu,
Gaofeng Zheng,
Yang Yang,
Qingxiao Chen,
Donghua He,
Yi Li,
zhen cai
Affiliations
Xincheng Jiang
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Xiaoyan Han
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Fengyan Jin
Department of Hematology, the First Hospital of Jilin University, Changchun, People’s Republic of China
Gang An
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People’s Republic of China
Jian Hou
Department of Hematology, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
Jingsong He
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Qingming Wang
Department of Hematology, the Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China
Wenjun Wu
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Yi Zhao
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Songfu Jiang
Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China
Shuchan Li
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Zhenshu Xu
Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
Gaofeng Zheng
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Yang Yang
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Qingxiao Chen
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Donghua He
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Yi Li
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
zhen cai
Department of Hematology and Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Objectives This study aims to assess the impact of the nationwide Omicron outbreak in December 2022 on Chinese patients with plasma cell disorders (PCD), focusing on the clinical characteristics of PCD patients with COVID-19 and the risk factors contributing to adverse clinical courses (severity and hospitalization) and outcomes.Methods A multicenter retrospective study was performed from December 1, 2022, to January 19, 2023. The study population includes 404 PCD patients, divided into a COVID-19 group (n = 342) and an uninfected group (n = 62).Results The frequency of COVID-19 infection was 84.7% (342/404), and 16.4% (56/342) were severe COVID-19. Among the 277 patients with complete follow-up, 2 deaths (0.7%) were reported, while 231 (83.4%) recovered from COVID-19. Age > 65 (P = 0.02) and prior anti-CD38 monoclonal antibody (mAb) treatment within six months (P = 0.03) were independent risk factors for severe infection. Additionally, previous chimeric antigen receptor T-cell (CAR-T) therapy within six months was correlated with a higher risk of hospitalization (P = 0.04) and prolonged recovery time (P = 0.03). No significant protective effect of vaccination on infection or severe infection was observed (P > 0.05).Conclusions The latest Omicron outbreak results in higher rates of severe infection and mortality in PCD patients compared with the general population in China, highlighting the need to protect this vulnerable population during the pandemic. Recent use of anti-CD38 mAb and CAR-T therapy are associated with poorer clinical courses and outcomes of PCD patients with COVID-19.
